Lingual alveolar soft part sarcoma responsive to pazopanib

A case report

Tomoyasu Yoshihiro, Kenji Tsuchihashi, Kenta Nio, Shuji Arita, Takafumi Nakano, Ryuji Yasumatsu, Rina Jiroumaru, hiroshi ariyama, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Rationale: The multi-targeted tyrosine kinase inhibitors such as cediranib, sunitinib and pazopanib have been reported to be effective for alveolar soft part sarcoma (ASPS). The efficacy of pazopanib for the patient with lingual ASPS has yet to be reported. Patient concerns: A 23-year old man presented with articulation disorder and swelling of the tongue. Diagnosis of lingual ASPS was made after incisional biopsy and complete excision of the mass was performed. Three months later, he presented with a protruding mental region. Diagnoses: Computed tomography revealed mental region mass and lung metastasis. Interventions: After the failure of combination therapy of doxorubicin and ifosfamide, pazopanib was administered. Outcomes: Shrinkage of both the mental region and lung mass continued for more than two months, but regrowth was confirmed at the fourth month. Lessons: Lingual ASPS is an exceedingly rare subset of ASPS with distinct molecular and histological characteristics and appropriate therapy remains to be established. Our findings suggest a possible therapeutic strategy for lingual ASPS.

元の言語英語
記事番号e8470
ジャーナルMedicine (United States)
96
発行部数44
DOI
出版物ステータス出版済み - 11 1 2017

Fingerprint

Alveolar Soft Part Sarcoma
Tongue
Articulation Disorders
Lung
Ifosfamide
Protein-Tyrosine Kinases
Doxorubicin
pazopanib
Therapeutics
Tomography
Neoplasm Metastasis
Biopsy

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Lingual alveolar soft part sarcoma responsive to pazopanib : A case report. / Yoshihiro, Tomoyasu; Tsuchihashi, Kenji; Nio, Kenta; Arita, Shuji; Nakano, Takafumi; Yasumatsu, Ryuji; Jiroumaru, Rina; ariyama, hiroshi; Kusaba, Hitoshi; Oda, Yoshinao; Akashi, Koichi; Baba, Eishi.

:: Medicine (United States), 巻 96, 番号 44, e8470, 01.11.2017.

研究成果: ジャーナルへの寄稿記事

@article{12d515c90df843a29c97b6101bca64c9,
title = "Lingual alveolar soft part sarcoma responsive to pazopanib: A case report",
abstract = "Rationale: The multi-targeted tyrosine kinase inhibitors such as cediranib, sunitinib and pazopanib have been reported to be effective for alveolar soft part sarcoma (ASPS). The efficacy of pazopanib for the patient with lingual ASPS has yet to be reported. Patient concerns: A 23-year old man presented with articulation disorder and swelling of the tongue. Diagnosis of lingual ASPS was made after incisional biopsy and complete excision of the mass was performed. Three months later, he presented with a protruding mental region. Diagnoses: Computed tomography revealed mental region mass and lung metastasis. Interventions: After the failure of combination therapy of doxorubicin and ifosfamide, pazopanib was administered. Outcomes: Shrinkage of both the mental region and lung mass continued for more than two months, but regrowth was confirmed at the fourth month. Lessons: Lingual ASPS is an exceedingly rare subset of ASPS with distinct molecular and histological characteristics and appropriate therapy remains to be established. Our findings suggest a possible therapeutic strategy for lingual ASPS.",
author = "Tomoyasu Yoshihiro and Kenji Tsuchihashi and Kenta Nio and Shuji Arita and Takafumi Nakano and Ryuji Yasumatsu and Rina Jiroumaru and hiroshi ariyama and Hitoshi Kusaba and Yoshinao Oda and Koichi Akashi and Eishi Baba",
year = "2017",
month = "11",
day = "1",
doi = "10.1097/MD.0000000000008470",
language = "English",
volume = "96",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "44",

}

TY - JOUR

T1 - Lingual alveolar soft part sarcoma responsive to pazopanib

T2 - A case report

AU - Yoshihiro, Tomoyasu

AU - Tsuchihashi, Kenji

AU - Nio, Kenta

AU - Arita, Shuji

AU - Nakano, Takafumi

AU - Yasumatsu, Ryuji

AU - Jiroumaru, Rina

AU - ariyama, hiroshi

AU - Kusaba, Hitoshi

AU - Oda, Yoshinao

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Rationale: The multi-targeted tyrosine kinase inhibitors such as cediranib, sunitinib and pazopanib have been reported to be effective for alveolar soft part sarcoma (ASPS). The efficacy of pazopanib for the patient with lingual ASPS has yet to be reported. Patient concerns: A 23-year old man presented with articulation disorder and swelling of the tongue. Diagnosis of lingual ASPS was made after incisional biopsy and complete excision of the mass was performed. Three months later, he presented with a protruding mental region. Diagnoses: Computed tomography revealed mental region mass and lung metastasis. Interventions: After the failure of combination therapy of doxorubicin and ifosfamide, pazopanib was administered. Outcomes: Shrinkage of both the mental region and lung mass continued for more than two months, but regrowth was confirmed at the fourth month. Lessons: Lingual ASPS is an exceedingly rare subset of ASPS with distinct molecular and histological characteristics and appropriate therapy remains to be established. Our findings suggest a possible therapeutic strategy for lingual ASPS.

AB - Rationale: The multi-targeted tyrosine kinase inhibitors such as cediranib, sunitinib and pazopanib have been reported to be effective for alveolar soft part sarcoma (ASPS). The efficacy of pazopanib for the patient with lingual ASPS has yet to be reported. Patient concerns: A 23-year old man presented with articulation disorder and swelling of the tongue. Diagnosis of lingual ASPS was made after incisional biopsy and complete excision of the mass was performed. Three months later, he presented with a protruding mental region. Diagnoses: Computed tomography revealed mental region mass and lung metastasis. Interventions: After the failure of combination therapy of doxorubicin and ifosfamide, pazopanib was administered. Outcomes: Shrinkage of both the mental region and lung mass continued for more than two months, but regrowth was confirmed at the fourth month. Lessons: Lingual ASPS is an exceedingly rare subset of ASPS with distinct molecular and histological characteristics and appropriate therapy remains to be established. Our findings suggest a possible therapeutic strategy for lingual ASPS.

UR - http://www.scopus.com/inward/record.url?scp=85033399313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033399313&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000008470

DO - 10.1097/MD.0000000000008470

M3 - Article

VL - 96

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 44

M1 - e8470

ER -